Emerging Frontiers and Opportunities: Special Populations and Technologies
Virtual ISPOR Europe 2021 is the leading European conference for HEOR, bringing together global leaders for discussion and dissemination of the latest trends in healthcare. This conference is made up Virtual ISPOR Europe 2021, which will take place 30 November-3 December, along with an in-person, Preconference Summit held 11 November at the Bella Center in Copenhagen, Denmark.
The conference theme for Virtual ISPOR Europe 2021 is “Emerging Frontiers and Opportunities: Special Populations and Technologies.” In recent years, rare diseases, digital therapeutics, personalized medicine, cell and gene therapies, and other new therapeutic approaches have stretched our data and methodological capabilities. Furthermore, issues associated with these special populations and technologies have important implications for a range of healthcare decisions, from regulatory pathways to coverage, reimbursement, and shared clinical decision-making. Virtual ISPOR Europe 2021 will feature HEOR scientists and stakeholders who work on these key challenges and highlight innovative solutions, advances in HEOR, as well as examples of how partnerships and dialogue with other disciplines are contributing to address these issues.
We are proud to present the following at ISPOR 2021, taking place virtually November 30 – December 3:
- Join Chris Cameron, MSc, PhD on this panel discussion on December 3 at 12:30:
CAN SINGLE-ARM TRIALS OF CAR-T THERAPIES MEET THE EVIDENCE REQUIREMENTS OF GLOBAL HEALTH TECHNOLOGY ASSESSMENT AGENCIES? ARE THERE INNOVATIVE WAYS TO ADDRESS THE COMPARATIVE EVIDENCE NEEDS?
This panel will debate whether single-arm studies of CAR-T therapies can meet the evidence requirements of global HTA bodies. Dr. Satish Valluri will moderate the panel and provide an overview of the current landscape of HTA requirements on comparative evidence for CAR-T therapies, as well as pose key questions for the panelists to debate, including:
- What are the challenges with conducting RCTs for CAR-T therapies?
- What are alternative approaches to RCTs that can generate robust comparative evidence?
- What role can RWE play in these situations?
- Under what clinical and methodological conditions is it sufficient to generate comparative data using RWE to justify the value of CAR-T therapies?
- Which methods are most acceptable from an HTA perspective, and what are the challenges?